Using VEGF Inhibitors to Treat Ovarian Cancer
Author Information
Author(s): Afshin Amini, Masoumi Moghaddam Samar, Morris David L., Pourgholami Mohammad H.
Primary Institution: The University of New South Wales
Hypothesis
Can targeting vascular endothelial growth factor (VEGF) improve treatment outcomes for ovarian cancer?
Conclusion
VEGF inhibitors show promise in treating ovarian cancer, but challenges such as resistance and side effects remain significant.
Supporting Evidence
- VEGF plays a crucial role in the progression of ovarian cancer.
- VEGF inhibitors have shown effectiveness in preclinical and clinical studies.
- Resistance to anti-VEGF therapy is a common issue in ovarian cancer treatment.
Takeaway
Doctors are trying to use special medicines that block a substance called VEGF to help treat ovarian cancer, which is a very serious disease.
Methodology
The article reviews various studies on the role of VEGF in ovarian cancer and the effectiveness of VEGF inhibitors.
Limitations
The study highlights the lack of predictive markers for treatment efficacy and the potential for resistance to therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website